Compare HNST & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HNST | CADL |
|---|---|---|
| Founded | 2012 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 249.3M | 280.3M |
| IPO Year | 2021 | 2021 |
| Metric | HNST | CADL |
|---|---|---|
| Price | $2.70 | $4.91 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | $3.00 | ★ $19.71 |
| AVG Volume (30 Days) | ★ 1.7M | 1.4M |
| Earning Date | 05-06-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 58.62 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $371,317,000.00 | $125,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.51 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.07 | $4.25 |
| 52 Week High | $5.52 | $8.69 |
| Indicator | HNST | CADL |
|---|---|---|
| Relative Strength Index (RSI) | 51.56 | 42.99 |
| Support Level | $2.38 | $4.57 |
| Resistance Level | $2.97 | $6.16 |
| Average True Range (ATR) | 0.13 | 0.23 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 41.30 | 38.52 |
The Honest Co Inc is a digitally-native consumer products company to makes purpose-driven consumer products designed for all people. It is an omnichannel brand, ensuring its products are available wherever its consumers shop through the company's Retail and Digital channels. It has three product categories namely; Diapers and Wipes, Skin and Personal Care, and Household and Wellness, out of which the majority of its revenue is generated from the sale of diapers and wipes. The company operates only in the United States.
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.